Kalaris Therapeutics, Inc. 8-K

What Happened
Kalaris Therapeutics, Inc. announced its financial results for the year ended December 31, 2025 in a press release issued on March 17, 2026. The company furnished the press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02: Results of Operations and Financial Condition).

Key Details

• Date of announcement: March 17, 2026.
• Reporting period: fiscal year ended December 31, 2025.
• The press release is furnished as Exhibit 99.1 to the Form 8-K (and the filing includes the Inline XBRL cover page as Exhibit 104).
• The company states the information is being furnished (not “filed”) and therefore is not subject to Section 18 liability or automatically incorporated by reference into other securities filings.

Why It Matters
This 8-K provides investors with Kalaris’s latest reported results for 2025 — including whatever revenue, expense, cash position or guidance details are in the press release. Retail investors should read Exhibit 99.1 (the March 17 press release) and any related SEC filings to see the specific financial metrics and assess impacts on valuation, liquidity, and near‑term plans. Because the release is furnished rather than filed, it’s being provided for information but carries different legal treatment than a filed disclosure.